# Micronuclei: origins, assays, mechanisms, diseases and treatments

**Authors:** Hailong Duan, Xin Peng, Sha Qin, Yanmin Zhou, Desheng Xiao, Yongguang Tao, Shuang Liu

PMC · DOI: 10.1038/s41392-025-02538-8 · Signal Transduction and Targeted Therapy · 2026-03-26

## TL;DR

This review explores micronuclei, their formation, role in genomic instability, and potential as therapeutic targets in diseases like cancer.

## Contribution

The paper provides a comprehensive overview of micronuclei's mechanisms, functions, and therapeutic potential.

## Key findings

- Micronuclei actively promote chromosomal instability and contribute to disease progression.
- Micronuclei may have functional roles beyond being biomarkers of genetic damage.
- Selective targeting of micronuclei for therapeutic use remains a challenge.

## Abstract

Micronuclei are small, independent cytoplasmic structures containing nuclear material. They typically form during cell division due to DNA damage or division abnormalities, serve as biomarkers of genetic damage, and are closely associated with chromosomal instability (CIN). Emerging evidence suggests that micronuclei actively promote and exacerbate CIN, with significant implications in disease pathology and potential therapeutic applications. This review provides a comprehensive overview of micronuclei by exploring their origins, formation mechanisms, and functional consequences, and detailing the fate of micronuclei post-formation, which is essential for elucidating their role in genomic instability and potential therapeutic implications. Furthermore, micronuclei can contribute to extreme chromosomal shattering and genomic instability. These processes are increasingly recognized as critical contributors to disease progression, particularly in cancer. Although micronuclei have traditionally been viewed as markers of genomic instability, recent evidence suggests that they may also serve functional roles. Their potential use as treatments for certain diseases appears theoretically feasible; however, challenges remain in selectively targeting cells to induce the formation of favorable micronuclei and maintain optimal immune responses. Addressing these questions could open new avenues for therapeutic interventions.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** SETD2 (SET domain containing 2, histone lysine methyltransferase) [NCBI Gene 29072] {aka HBP231, HIF-1, HIP-1, HSPC069, HYPB, KMT3A}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, FAN1 (FANCD2 and FANCI associated nuclease 1) [NCBI Gene 22909] {aka KIAA1018, KMIN, MTMR15, hFAN1}, CIMAP2 (ciliary microtubule associated protein 2) [NCBI Gene 163747] {aka C1orf177, LEM, LEXM}, KNL1 (kinetochore scaffold 1) [NCBI Gene 57082] {aka AF15Q14, CASC5, CT29, D40, MCPH4, PPP1R55}, TERF1 (telomeric repeat binding factor 1) [NCBI Gene 7013] {aka PIN2, TRBF1, TRF, TRF1, hTRF1-AS, t-TRF1}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, SLX4 (SLX4 structure-specific endonuclease subunit) [NCBI Gene 84464] {aka BTBD12, FANCP, MUS312}, STK11 (serine/threonine kinase 11) [NCBI Gene 6794] {aka LKB1, PJS, hLKB1}, POT1 (protection of telomeres 1) [NCBI Gene 25913] {aka CMM10, CRMCC3, GLM9, HPOT1, PFBMFT8, TPDS3}, DSCC1 (DNA replication and sister chromatid cohesion 1) [NCBI Gene 79075] {aka DCC1}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, STING1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 340061] {aka ERIS, MITA, MPYS, NET23, SAVI, STING}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, H2AC18 (H2A clustered histone 18) [NCBI Gene 8337] {aka H2A, H2A.2, H2A/O, H2A/q, H2AFO, H2a-615}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, OGG1 (8-oxoguanine DNA glycosylase) [NCBI Gene 4968] {aka HMMH, HOGG1, MUTM, OGH1}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, FANCM (FA complementation group M) [NCBI Gene 57697] {aka FAAP250, KIAA1596, POF15, SPGF28}, BAP1 (BRCA1 associated deubiquitinase 1) [NCBI Gene 8314] {aka HUCEP-13, KURIS, TPDS1, UBM2, UCHL2, UVM2}, Atg7 (autophagy related 7) [NCBI Gene 74244] {aka 1810013K23Rik, Agp7, Apg7l, Atg7l, Gm21553}, Dscc1 (DNA replication and sister chromatid cohesion 1) [NCBI Gene 72107] {aka 2010006I05Rik, 2600005O03Rik, Dcc1}, LMNA (lamin A/C) [NCBI Gene 4000] {aka CDCD1, CDDC, CMD1A, CMT2B1, EMD2, FPL}, MXD1 (MAX dimerization protein 1) [NCBI Gene 4084] {aka BHLHC58, MAD, MAD1}, TOPBP1 (DNA topoisomerase II binding protein 1) [NCBI Gene 11073] {aka Dpb11, TOP2BP1}, CENPA (centromere protein A) [NCBI Gene 1058] {aka CENP-A, CenH3}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, PRKDC (protein kinase, DNA-activated, catalytic subunit) [NCBI Gene 5591] {aka DNA-PKC, DNA-PKcs, DNAPK, DNAPKc, DNPK1, HYRC}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}, POLQ (DNA polymerase theta) [NCBI Gene 10721] {aka PRO0327}, TAS2R62P (taste 2 receptor member 62, pseudogene) [NCBI Gene 338399] {aka PS1, T2R62, TAS2R62}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, NBN (nibrin) [NCBI Gene 4683] {aka AT-V1, AT-V2, ATV, NBS, NBS1, P95}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, FANCG (FA complementation group G) [NCBI Gene 2189] {aka FAG, XRCC9}, ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289] {aka B120, BAF250, BAF250a, BM029, C1orf4, CSS2}, TINF2 (TERF1 interacting nuclear factor 2) [NCBI Gene 26277] {aka DKCA3, DKCA5, TIN2}, FANCA (FA complementation group A) [NCBI Gene 2175] {aka FA, FA-H, FA1, FAA, FACA, FAH}, CENPC (centromere protein C) [NCBI Gene 1060] {aka CENP-C, CENPC1, MIF2, hcp-4}, FANCF (FA complementation group F) [NCBI Gene 2188] {aka FAF}, TBK1 (TANK binding kinase 1) [NCBI Gene 29110] {aka AIARV, FTDALS4, IIAE8, NAK, T2K}, NDC80 (NDC80 kinetochore complex component) [NCBI Gene 10403] {aka HEC, HEC1, HsHec1, KNTC2, TID3, hsNDC80}, MIS12 (MIS12 kinetochore complex component) [NCBI Gene 79003] {aka 2510025F08Rik, KNTC2AP, MTW1, hMis12}, LMNB1 (lamin B1) [NCBI Gene 4001] {aka ADLD, LMN, LMN2, LMNB, MCPH26}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 66734] {aka 1010001H21Rik, 4922501H04Rik, LC3, LC3a}, RAD50 (RAD50 double strand break repair protein) [NCBI Gene 10111] {aka NBSLD, RAD502, hRad50}, Atg14 (autophagy related 14) [NCBI Gene 100504663] {aka 4832427M01, Atg14L, D14Ertd114e, D14Ertd436e}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, OGA (O-GlcNAcase) [NCBI Gene 10724] {aka MEA5, MGEA5, NCOAT}, CENPB (centromere protein B) [NCBI Gene 1059], IRF3 (interferon regulatory factor 3) [NCBI Gene 3661] {aka IIAE7}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}
- **Diseases:** hypoxia (MESH:D000860), metastasis (MESH:D009362), deterioration (MESH:D000075902), prostate cancer (MESH:D011471), acute leukemia (MESH:D015470), WHIM syndrome (MESH:C536697), tumorigenesis (MESH:D063646), Multiple sclerosis (MESH:D009103), lung cancer (MESH:D008175), breast ductal carcinoma (MESH:D018270), deficient abnormalities of bone (MESH:D001847), triple-negative breast cancer (MESH:D064726), Li-Fraumeni syndrome (MESH:D016864), bone cancer (MESH:D001859), CIN cancer (MESH:D009369), multiple myeloma (MESH:D009101), PDAC (MESH:D021441), breast, lung, pancreatic, thyroid, and head and neck cancers (MESH:C537262), CLL (MESH:D015451), Reproductive disorders (MESH:D060737), erythema (MESH:D004890), folate deficiency (MESH:C562799), melanoma (MESH:D008545), neuroblastoma (MESH:D009447), congenital malformations (OMIM:163000), nuclear pore complex (MESH:C565375), autoimmune disease (MESH:D001327), Sonic Hedgehog medulloblastoma (MESH:D008527), fistulae (MESH:D005402), mitochondrial dysfunction (MESH:D028361), COPD (MESH:D029424), neuronal function (MESH:D009410), genetic immunodeficiency (MESH:D007153), CRC (MESH:D015179), ovarian cancer (MESH:D010051), precancerous lesions (MESH:D011230), uveal melanoma (MESH:C536494), osteosarcoma (MESH:D012516), CIN (MESH:D043171), congenital diseases (MESH:D030342), ICF (MESH:C537362), Micronuclei (MESH:D048629), blood diseases (MESH:D006402), Infertility (MESH:D007246), Neurodegenerative diseases (MESH:D019636), inflammation (MESH:D007249), Huntington's disease (MESH:D006816), developmental abnormalities (MESH:D006130), immune disorder (MESH:D007154), breast and liver cancer (MESH:D001943), cytotoxic (MESH:D064420), FAP (MESH:D011125), burns (MESH:D002056), NSCLC (MESH:D002289), gastric cardia adenocarcinoma (MESH:D004938), PD (MESH:D010300), cervical cancer (MESH:D002583), cognitive, motor, and other functional impairments (MESH:D003072), FA (MESH:D005199), aneuploidy (MESH:D000782)
- **Chemicals:** Paclitaxel (MESH:D017239), 8-oxo guanine (MESH:C024829), nocodazole (MESH:D015739), cGAMP (MESH:C584311), cysteine (MESH:D003545), MMC (MESH:D016685), Cytochalasin B (MESH:D003571), 2'3'- cGAMP (-), ROS (MESH:D017382), folate (MESH:D005492), AZD6738 (MESH:C000611951), CFI-402257 (MESH:C000625147), levodopa (MESH:D007980), cisplatin (MESH:D002945), deoxyinosine (MESH:C012271), camptothecin (MESH:D002166), alcohol (MESH:D000438), DAPI (MESH:C007293), HU (MESH:D006918), sucrose (MESH:D013395), ATP (MESH:D000255), acridine orange (MESH:D000165), 8-oxo-7,8-dihydro-2'-deoxyguanosine (MESH:D000080242)
- **Species:** Paracentrotus lividus (common sea urchin, species) [taxon 7656], Vicia faba (broad bean, species) [taxon 3906], Medicago sativa (alfalfa, species) [taxon 3879], Mus musculus (house mouse, species) [taxon 10090], Rodentia (rodent, order) [taxon 9989], Felis catus (cat, species) [taxon 9685], Methanoculleus sp. dm2 (species) [taxon 224721], Homo sapiens (human, species) [taxon 9606], Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932]
- **Mutations:** G12D, C1245G
- **Cell lines:** A549 — Homo sapiens (Human), Lung adenocarcinoma, Cancer cell line (CVCL_0023), RPE-1 — Homo sapiens (Human), Telomerase immortalized cell line (CVCL_4388), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), DLD-1 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0248), MCF10A — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_0598), BT-549 — Homo sapiens (Human), Invasive breast carcinoma of no special type, Cancer cell line (CVCL_1092), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062), SHH-MB — Homo sapiens (Human), Medulloblastoma, Cancer cell line (CVCL_M703)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13022493/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13022493/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC13022493/full.md

---
Source: https://tomesphere.com/paper/PMC13022493